Carregant...
Mechanisms of resistance to FLT3 inhibitors
The success of the small molecule tyrosine kinase receptor inhibitor (TKI) imatinib mesylate (Gleevec) in the treatment of chronic myeloid leukemia (CML) constitutes an eminent paradigm shift advocating the rational design of cancer therapeutics specifically targeting the transformation events that...
Guardat en:
| Publicat a: | Drug Resist Updat |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891941/ https://ncbi.nlm.nih.gov/pubmed/19162530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drup.2008.12.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|